Pancreatic cancer is a leading cause of cancer death worldwide and its global burden has
more than doubled over the past 25 years. The highest incidence regions for pancreatic …

Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Pancreatic cancer usually results in poor survival with limited options for treatment, as most
affected individuals present with advanced disease. Early detection of preinvasive …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Pancreatic cancer is the fourth leading cause of cancer-related death among men and
women in the United States. A major challenge in treatment remains patients' advanced …

Most patients with pancreatic ductal adenocarcinoma (PDAC) present with symptomatic,
surgically unresectable disease. Although the goal of early detection of PDAC is laudable …

Background and aim The International Cancer of the Pancreas Screening Consortium met in
2018 to update its consensus recommendations for the management of individuals with …

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide with
432,242 related deaths in 2018. Unlike other cancers, the incidence of pancreatic cancer …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future.
Here we describe our efforts to develop a noninvasive blood test for the detection of …